Report overview
Oncology Immunotherapy exploits virus's ability to replicate selectively and kill tumor tissue while at the same time regulate the specific immune response of a patient The first oncolytic virus to demonstrate a clinical benefit in patients with melanoma is genetically modified herpes simplex virus type I i.e. Talimogene laherparepvec (T-VEC).
This report aims to provide a comprehensive presentation of the global market for Oncolytic Virus Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncolytic Virus Immunotherapy. This report contains market size and forecasts of Oncolytic Virus Immunotherapy in global, including the following market information:
Global Oncolytic Virus Immunotherapy Market Revenue, 2018-2023, 2024-2035, ($ millions)
Global top five companies in 2022 (%)
The global Oncolytic Virus Immunotherapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2035, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North America is leading in the oncolytic virus immunotherapy market globally, according to Skin Cancer Foundation Statistics, Globally 132,000 melanoma skin cancers occur each year. One in every three cancers diagnosed is a skin cancer, and one in every five Americans will develop skin cancer in their lifetime. North America has well-developed healthcare infrastructure with massive investment in research and development of oncolytic virus immunotherapy.
We surveyed the Oncolytic Virus Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oncolytic Virus Immunotherapy Market, by Type, 2018-2023, 2024-2035 ($ millions)
Global Oncolytic Virus Immunotherapy Market Segment Percentages, by Type, 2022 (%)
Engineering Oncolytic Viruses
Wild-Type Oncolytic Viruses
Global Oncolytic Virus Immunotherapy Market, by Application, 2018-2023, 2024-2035 ($ millions)
Global Oncolytic Virus Immunotherapy Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Ambulatory Surgical Centers
Global Oncolytic Virus Immunotherapy Market, By Region and Country, 2018-2023, 2024-2035 ($ Millions)
Global Oncolytic Virus Immunotherapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oncolytic Virus Immunotherapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Oncolytic Virus Immunotherapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Amgen
TILT Biotherapeutics
Oncorus
Sorrento Therapeutics
Shanghai Sunway Biotech
Outline of Major Chapters:
Chapter 1: Introduces the definition of Oncolytic Virus Immunotherapy, market overview.
Chapter 2: Global Oncolytic Virus Immunotherapy market size in revenue.
Chapter 3: Detailed analysis of Oncolytic Virus Immunotherapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oncolytic Virus Immunotherapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
